LAROTRECTINIB SULFATE | BAYER HLTHCARE | ||
EQ 25MG BASE,EQ 100MG BASE | |||
No | No | ||
2036-Aug-15 | 2023-Nov-26 | ||
None | None | ||
None | No | ||
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. |
0 | 0 | 0 |
Total Other Developers | 5 |
---|
Drugs with Suitability | No |
---|
EQ 25MG BASE | ** | ** | - | - | - |
EQ 100MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com